Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28293955 | 0.78 | ALDH1A1 (0.42) | CPA1ALDH1A1CYP2C19 | |
| SCHEMBL28677669 | 0.76 | CPA1 (0.41) | CPA1ALDH1A1 | |
| SCHEMBL19853003 | 0.75 | CPA1 (0.39) | CPA1ALDH1A1CYP2C19 | |
| SCHEMBL15779329 | 0.73 | CTSK (0.40) | ALDH1A1CYP2C19 | |
| SCHEMBL116798 | 0.73 | OR51E2 (0.40) | — | |
| SCHEMBL473223 | 0.73 | TSHR (0.36) | — | |
| SCHEMBL1485462 | 0.73 | TSHR (0.36) | — | |
| SCHEMBL473139 | 0.73 | TSHR (0.36) | — | |
| SCHEMBL5667907 | 0.71 | NOS1 (0.35) | — | |
| SCHEMBL6799320 | 0.71 | NOS1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139514-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-2301911-B1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-08-19 | — | — | EP | disclosed |
| CN-102046592-B | Preparation method of oseltamivir phosphate and intermediate compound | UNIV TOKYO SCI EDUC FOUND | 2014-12-10 | — | — | CN | disclosed |
| US-20130296600-A1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2013-11-07 | — | — | US | disclosed |
| CN-103288696-A | Intermediate compound of oseltamivir phosphate | UNIV TOKYO SCI EDUC FOUND | 2013-09-11 | — | — | CN | disclosed |
| US-8501980-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| CN-102046592-A | Preparation method of oseltamivir phosphate and intermediate compound | UNIV TOKYO SCI EDUC FOUND | 2011-05-04 | — | — | CN | disclosed |
| US-20110082302-A1 | Process for Producing Oseltamivir Phosphate and Intermediate Compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2301911-A1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | Tokyo University Of Science Educational Foundation Administrative Organization (JP) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082302-A1 | Process for Producing Oseltamivir Phosphate and Intermediate Compound | CYP2B6, CYP2D6, UMPS | CPA1 3478/4885ITGA4 1396/4885ITGB7 1975/4885 |
| US-20130296600-A1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | CYP2B6, CYP2D6, UMPS | CPA1 3478/4885ITGA4 1396/4885ITGB7 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.